IDEAYA shares ESMO 2026 data updates for darovasertib trials in uveal melanoma

IDYA•2026-07-17

Planned registrational trial timing

Hengrui targets starting the first registrational trial for IDE849 by year-end in China, with initiation also planned in other regions including the U.S.

Partner Hengrui to present IDE849 results

Partner Hengrui plans to present long-term Phase 1 results for IDE849 (SHR-4849), a DLL3 TOP1 ADC, in relapsed small cell lung cancer and other NECs.

ESMO 2026 updates for darovasertib programs

IDEAYA Biosciences flagged new clinical data disclosures at ESMO 2026 for darovasertib across metastatic and neoadjuvant uveal melanoma programs.

IDEAYA shares ESMO 2026 data updates for darovasertib trials in uveal melanoma

Planned registrational trial timing

Partner Hengrui to present IDE849 results

ESMO 2026 updates for darovasertib programs

Related News

Erock Inc <EROC.N>: Bofa Global Research Raises to Buy From Neutral

Nasdaq trade halt continues VIVK volatility trading pause at 10:13 AM

Tri City Bankshares FY26 H1 net income climbs 24.7% to $8.1 million

TABLE-U.S. June industrial output rises 0.1 percent

Nasdaq trade halt <VEEE.O> volatility trading pause at 09:53 AM